Trowaglerix Venom Polypeptides As a Novel Antithrombotic Agent by Targeting Immunoglobulin-Like Domains of Glycoprotein VI in Platelet
Arteriosclerosis, thrombosis, and vascular biology | 10 Jun 2017
CH Chang, CH Chung, YS Tu, CC Tsai, CC Hsu, HC Peng, YJ Tseng and TF Huang
Currently prescribed antiplatelet drugs have 1 common side effect-an increased risk of hemorrhage and thrombocytopenia. On the contrary, bleeding defects associated with glycoprotein VI (GPVI) expression deficiency are usually slightly prolonged bleeding times. However, GPVI antagonists are lacking in clinic.
* Data courtesy of Altmetric.com